Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment

Overview of attention for article published in Frontiers in oncology, October 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 24,518 followers.

Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment https://t.co/7OKbn4XdCh https://t.co/gNPGN9PtEX

01 Nov 2022

Reply Repost Favourite

RT @FrontOncology: New research: Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential ty…

01 Nov 2022

Reply Repost Favourite

New research: Case report: A novel reciprocal ROS1-CD74 fusion in a NSCLC patient partially benefited from sequential tyrosine kinase inhibitors treatment: Background The clinical significance of majority oncogenic novel fusions is still… https://t.co/3UI

31 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.